Literature DB >> 8527226

Dietary management of X-linked adrenoleukodystrophy.

H W Moser1, J Borel.   

Abstract

Adrenoleukodystrophy (ALD) is an X-linked disorder that involves mainly the nervous system white matter and adrenal cortex. It is associated with the accumulation of saturated very-long-chain fatty acids (VLCFAs), such as hexacosanoic acid (C26:0), that occurs as a result of the impaired capacity to degrade these substances, a reaction that normally takes place in the peroxisome. The VLCFAs originate from the diet and are also synthesized endogenously. Interest in dietary therapy arose from the observation that the administration of oils containing erucic and oleic acid (Lorenzo's oil), when combined with restriction of dietary intake of VLCFAs, can normalize plasma VLCFA levels in ALD patients. Clinical results in patients who are already symptomatic have been disappointing. However, preliminary data, still in need of confirmation, suggest that dietary therapy begun in asymptomatic patients can reduce the frequency and severity of later neurological disability.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527226     DOI: 10.1146/annurev.nu.15.070195.002115

Source DB:  PubMed          Journal:  Annu Rev Nutr        ISSN: 0199-9885            Impact factor:   11.848


  11 in total

1.  Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

Authors:  B M van Geel; J Assies; E B Haverkort; J H Koelman; B Verbeeten; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Cerebellar Ataxia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

Review 3.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

4.  A mouse model for X-linked adrenoleukodystrophy.

Authors:  J F Lu; A M Lawler; P A Watkins; J M Powers; A B Moser; H W Moser; K D Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 5.  Very long-chain fatty acids in diagnosis, pathogenesis, and therapy of peroxisomal disorders.

Authors:  H W Moser; A B Moser
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

6.  Synthesis of esters of androgens with unsaturated fatty acids for androgen requiring therapy.

Authors:  F Aiello; A Garofalo; A M Aloisi; S Lamponi; A Magnani; A Petroni
Journal:  J Endocrinol Invest       Date:  2012-10-22       Impact factor: 4.256

7.  Plasma and red blood cell fatty acids in peroxisomal disorders.

Authors:  A B Moser; D S Jones; G V Raymond; H W Moser
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

8.  Long-chain monounsaturated Fatty acids and incidence of congestive heart failure in 2 prospective cohorts.

Authors:  Fumiaki Imamura; Rozenn N Lemaitre; Irena B King; Xiaoling Song; Lyn M Steffen; Aaron R Folsom; David S Siscovick; Dariush Mozaffarian
Journal:  Circulation       Date:  2013-03-13       Impact factor: 29.690

9.  Fast diffusion of very long chain saturated fatty acids across a bilayer membrane and their rapid extraction by cyclodextrins: implications for adrenoleukodystrophy.

Authors:  Biju K Pillai; Ravi Jasuja; Jeffrey R Simard; James A Hamilton
Journal:  J Biol Chem       Date:  2009-09-28       Impact factor: 5.157

10.  In vivo gene editing via homology-independent targeted integration for adrenoleukodystrophy treatment.

Authors:  Sung-Ah Hong; Jung Hwa Seo; Soohyun Wi; Eul Sik Jung; Jihyeon Yu; Gue-Ho Hwang; Ji Hea Yu; Ahreum Baek; Soeon Park; Sangsu Bae; Sung-Rae Cho
Journal:  Mol Ther       Date:  2021-05-29       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.